Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Pittman

Showing results (91-100 of 222) with videos related to

Pageof 23
Sort By:
Psychopharmacology|June 13, 2019
Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humansMohini Ranganathan, Joao P De Aquino, Jose A Cortes-Briones, et al.
Alcohol, Clinical & Experimental Research|June 26, 2025
Pain interference, alcohol use, and metabolic health: Insights from a nationally representative studyGabriel P A Costa, Rebecca Suh, Julio C Nunes, et al.
Journal of Psychopharmacology (Oxford, England)|March 13, 2025
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-reportShashwath A Meda, Michael C Stevens, Erwin R Boer, et al.
Addiction Biology|August 30, 2023
Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory studyJoao P De Aquino, Julia Meyerovich, Catherine Z Xie, et al.
Psychiatry Research|January 15, 2011
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRSGerald W Valentine, Graeme F Mason, Rosane Gomez, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 9, 2015
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of AmphetamineKyung-Heup Ahn, Andrew Sewell, Jacqueline Elander, et al.
Journal of Studies on Alcohol and Drugs|June 19, 2025
Cognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomesNoah R Wolkowicz, Brian Pittman, Shannon W Schrader, et al.
Journal of Neurochemistry|September 17, 2013
Metabolic products of [2-(13) C]ethanol in the rat brain after chronic ethanol exposureJie Wang, Hongying Du, Xiaoxian Ma, et al.
BMC Psychology|March 29, 2022
Personality as a mediator of autistic traits and internalizing symptoms in two community samplesOlivia N Grella, Amanda Dunlap, Alycia M Nicholson, et al.
Addictive Behaviors|October 5, 2010
Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA)Robert T Malison, Rasmon Kalayasiri, Kittipong Sanichwankul, et al.
Pageof 23

Showing results (91-100 of 222) with videos related to

Sort By:
Pageof 23
Psychopharmacology|June 13, 2019
Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humansMohini Ranganathan, Joao P De Aquino, Jose A Cortes-Briones, et al.
Alcohol, Clinical & Experimental Research|June 26, 2025
Pain interference, alcohol use, and metabolic health: Insights from a nationally representative studyGabriel P A Costa, Rebecca Suh, Julio C Nunes, et al.
Journal of Psychopharmacology (Oxford, England)|March 13, 2025
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-reportShashwath A Meda, Michael C Stevens, Erwin R Boer, et al.
Addiction Biology|August 30, 2023
Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory studyJoao P De Aquino, Julia Meyerovich, Catherine Z Xie, et al.
Psychiatry Research|January 15, 2011
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRSGerald W Valentine, Graeme F Mason, Rosane Gomez, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 9, 2015
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of AmphetamineKyung-Heup Ahn, Andrew Sewell, Jacqueline Elander, et al.
Journal of Studies on Alcohol and Drugs|June 19, 2025
Cognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomesNoah R Wolkowicz, Brian Pittman, Shannon W Schrader, et al.
Journal of Neurochemistry|September 17, 2013
Metabolic products of [2-(13) C]ethanol in the rat brain after chronic ethanol exposureJie Wang, Hongying Du, Xiaoxian Ma, et al.
BMC Psychology|March 29, 2022
Personality as a mediator of autistic traits and internalizing symptoms in two community samplesOlivia N Grella, Amanda Dunlap, Alycia M Nicholson, et al.
Addictive Behaviors|October 5, 2010
Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA)Robert T Malison, Rasmon Kalayasiri, Kittipong Sanichwankul, et al.
Pageof 23